Latest Insider Transactions at Protara Therapeutics, Inc. (TARA)
This section provides a real-time view of insider transactions for Protara Therapeutics, Inc. (TARA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Protara Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Protara Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
126,301
-9.21%
|
$126,301
$1.71 P/Share
|
|
Sep 11
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,600
-2.25%
|
$32,600
$1.71 P/Share
|
|
Sep 10
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,500
-1.94%
|
$25,500
$1.77 P/Share
|
|
Sep 09
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,492
-2.48%
|
$36,492
$1.89 P/Share
|
|
Aug 28
2024
|
Jesse Shefferman CEO and President |
SELL
Bona fide gift
|
Direct |
8,563
-0.45%
|
-
|
|
Jul 16
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
11,396
-3.1%
|
$22,792
$2.44 P/Share
|
|
Jul 11
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
47,993
-10.75%
|
$95,986
$2.4 P/Share
|
|
Jul 10
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,061
-3.42%
|
$36,122
$2.31 P/Share
|
|
Jul 09
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,497
-1.65%
|
$16,994
$2.21 P/Share
|
|
Jul 01
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,288
-1.52%
|
$16,576
$2.12 P/Share
|
|
Jun 28
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,994
-3.07%
|
$35,988
$2.07 P/Share
|
|
Jun 27
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
46,574
-6.84%
|
$93,148
$2.26 P/Share
|
|
Jun 25
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,725
-3.01%
|
$25,450
$2.26 P/Share
|
|
May 31
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,824
-5.09%
|
$11,648
$2.9 P/Share
|
|
May 30
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,230
-7.46%
|
$18,460
$2.94 P/Share
|
|
May 22
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,800
-0.4%
|
$29,400
$3.01 P/Share
|
|
May 21
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
33,000
-1.39%
|
$99,000
$3.06 P/Share
|
|
May 17
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
70,885
-1.47%
|
$212,655
$3.2 P/Share
|
|
May 10
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
151,700
-5.99%
|
$455,100
$3.11 P/Share
|
|
May 09
2024
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,600
-1.19%
|
$91,800
$3.09 P/Share
|
|
Jan 19
2024
|
Hannah Fry VP, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
904
-2.94%
|
$904
$1.91 P/Share
|
|
Jan 19
2024
|
Hannah Fry VP, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+20.65%
|
-
|
|
Jan 19
2024
|
Patrick Fabbio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+50.0%
|
-
|
|
Jan 19
2024
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
3,049
-2.84%
|
$3,049
$1.91 P/Share
|
|
Jan 19
2024
|
Jacqueline Zummo Chf Scientific Operations Off |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+17.65%
|
-
|
|
Jan 19
2024
|
Jathin Bandari Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,879
-4.83%
|
$2,879
$1.91 P/Share
|
|
Jan 19
2024
|
Jathin Bandari Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+27.85%
|
-
|
|
Jan 19
2024
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
7,803
-0.82%
|
$7,803
$1.91 P/Share
|
|
Jan 19
2024
|
Jesse Shefferman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
59,000
+5.84%
|
-
|
|
Jan 10
2024
|
Jathin Bandari Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,877
-4.88%
|
$3,754
$2.39 P/Share
|
|
Jan 10
2024
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
5,229
-5.84%
|
$10,458
$2.39 P/Share
|
|
Jan 10
2024
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,746
-0.64%
|
$11,492
$2.39 P/Share
|
|
Jan 03
2024
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
1,899
-2.08%
|
$3,798
$2.17 P/Share
|
|
Jan 03
2024
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,840
-0.65%
|
$11,680
$2.17 P/Share
|
|
Jan 03
2024
|
Hannah Fry VP, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
324
-1.4%
|
$648
$2.17 P/Share
|
|
Jul 17
2023
|
Hannah Fry VP, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
10,075
-30.4%
|
$20,150
$2.56 P/Share
|
|
Jul 03
2023
|
Jathin Bandari Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
682
-1.74%
|
$1,364
$2.46 P/Share
|
|
Jun 27
2023
|
Jesse Shefferman CEO and President |
SELL
Bona fide gift
|
Direct |
7,420
-0.81%
|
-
|
|
Jun 23
2023
|
Jesse Shefferman CEO and President |
SELL
Bona fide gift
|
Direct |
1,890
-0.21%
|
-
|
|
Jan 19
2023
|
Jathin Bandari Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,700
+34.59%
|
-
|
|
Jan 19
2023
|
Jacqueline Zummo Chf Scientific Operations Off |
BUY
Grant, award, or other acquisition
|
Direct |
19,900
+17.87%
|
-
|
|
Jan 19
2023
|
Hannah Fry VP, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+15.11%
|
-
|
|
Jan 19
2023
|
Jesse Shefferman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
51,300
+5.29%
|
-
|
|
Jan 10
2023
|
Jathin Bandari Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,876
-9.23%
|
$5,628
$3.0 P/Share
|
|
Jan 10
2023
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,855
-0.67%
|
$17,565
$3.0 P/Share
|
|
Jan 10
2023
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
5,225
-6.8%
|
$15,675
$3.0 P/Share
|
|
Jan 03
2023
|
Hannah Fry VP, Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
361
-1.31%
|
$722
$2.8 P/Share
|
|
Jan 03
2023
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,604
-0.75%
|
$13,208
$2.8 P/Share
|
|
Jan 03
2023
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,159
-2.73%
|
$4,318
$2.8 P/Share
|
|
Dec 30
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private sale
|
Indirect |
15,473
+1.12%
|
$30,946
$2.71 P/Share
|